InvestorsHub Logo
Followers 72
Posts 2623
Boards Moderated 0
Alias Born 03/01/2013

Re: None

Wednesday, 09/09/2020 4:37:08 PM

Wednesday, September 09, 2020 4:37:08 PM

Post# of 225
"Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207."

https://finance.yahoo.com/news/compugen-starts-dosing-early-stage-053529308.html


I can see CGEN at $60-$75 per share min next year if a buyout occurs. I know a lot of heavy hitters are watching this and a working partnership with Bristol Myers Squibb, a 140 billion dollar beast is very encouraging.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CGEN News